Anthera Pharmaceuticals, Inc. (ANTH) — AI-Aktienanalyse

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for unmet medical needs. Their pipeline includes Sollpura for exocrine pancreatic insufficiency and Blisibimod for B-cell mediated autoimmune diseases.

Unternehmensueberblick

Kurzfassung:

Anthera Pharmaceuticals, Inc. operates in the biotechnology sector, focusing on developing therapies for unmet medical needs. Their pipeline features Sollpura, a non-porcine pancreatic enzyme replacement therapy, and Blisibimod, targeting autoimmune diseases. The company navigates the competitive landscape of biopharmaceutical development with licensing agreements to bolster its portfolio.

Ueber ANTH

Founded in 2004 and based in Houston, Texas, Anthera Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative medicines for patients with unmet medical needs. The company's primary focus is on addressing diseases with limited or inadequate treatment options, striving to improve patient outcomes and quality of life. Anthera's lead product candidates include Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy currently in Phase III clinical trials for the treatment of exocrine pancreatic insufficiency (EPI). EPI is a condition where the pancreas does not produce enough enzymes to digest food properly. Additionally, Anthera is developing Blisibimod, a drug in Phase II clinical trials for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy (IgA nephropathy), a kidney disease. Anthera has established strategic collaborations through license agreements with major pharmaceutical companies like Amgen, Inc., and Eli Lilly and Company, enhancing its research and development capabilities and expanding its therapeutic pipeline. The company's commitment to innovation and patient-centric drug development positions it within the competitive biotechnology landscape.

Investmentthese

Anthera Pharmaceuticals, Inc. presents a high-risk, high-reward investment profile within the biotechnology sector. The company's value hinges on the successful completion of clinical trials for Sollpura and Blisibimod. Positive Phase III results for Sollpura could drive significant market capitalization growth, addressing the unmet need for non-porcine pancreatic enzyme replacement therapy. However, the company's OTC listing and negative beta of -123.12 indicate substantial volatility and speculative trading. The lack of current revenue and reliance on future drug approvals create significant financial risk. Investors should closely monitor clinical trial outcomes and regulatory milestones to assess the potential for long-term value creation. The company's success is contingent on navigating the complex regulatory landscape and securing commercial partnerships.

Branchenkontext

Anthera Pharmaceuticals, Inc. operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The industry is driven by innovation, with companies constantly seeking to develop novel treatments for unmet medical needs. Anthera's focus on exocrine pancreatic insufficiency and autoimmune diseases positions it within specific niches of the broader pharmaceutical market. Competitors include companies developing similar therapies, as well as established pharmaceutical giants. The company's success depends on its ability to navigate the regulatory landscape, secure funding, and effectively commercialize its products.

Biotechnology

Healthcare

Wachstumschancen

Expansion into New Therapeutic Areas: Anthera could leverage its expertise in drug development to expand into new therapeutic areas with unmet medical needs, such as rare diseases or oncology. This diversification could reduce the company's reliance on its current pipeline and create new revenue streams. The market for rare disease therapies is projected to reach $258 billion by 2030, offering significant growth potential.
Geographic Expansion: Anthera could expand its commercial operations into new geographic markets, particularly in Asia and Europe, where there is a growing demand for advanced therapies. This expansion could increase the company's revenue and market share. The global pharmaceutical market is expected to reach $1.5 trillion by 2026, with emerging markets driving much of the growth.
Strategic Partnerships and Acquisitions: Anthera could pursue strategic partnerships or acquisitions to expand its pipeline, access new technologies, or strengthen its market position. This could accelerate the company's growth and create synergies. The biotechnology industry is characterized by frequent mergers and acquisitions, with companies seeking to consolidate their market share and expand their capabilities.
Orphan Drug Designation: Anthera can pursue orphan drug designation for its therapies targeting rare diseases. This designation provides incentives such as market exclusivity, tax credits, and reduced regulatory fees, enhancing the commercial viability of these products. The orphan drug market is growing rapidly, driven by increasing awareness of rare diseases and the development of new therapies.
Advancements in Drug Delivery Technologies: Anthera can invest in innovative drug delivery technologies to improve the efficacy and patient compliance of its therapies. This could create a competitive advantage and increase the market potential of its products. The drug delivery market is expected to reach $240 billion by 2028, driven by the development of new and improved delivery systems.

Sollpura is in Phase III clinical trial for exocrine pancreatic insufficiency, representing a potential near-term value driver.
Blisibimod is in Phase II clinical trial for B-cell mediated autoimmune diseases, indicating a longer-term growth opportunity.
The company has license agreements with Amgen, Inc., and Eli Lilly and Company, providing potential revenue streams and validation of its technology.
Anthera Pharmaceuticals, Inc. operates with a small team of 21 employees, suggesting a lean operational structure.
The company's stock trades on the OTC market, indicating higher risk and volatility compared to major exchange listings.

Was das Unternehmen tut

Develops Sollpura, a non-porcine pancreatic enzyme replacement therapy.
Conducts Phase III clinical trials for Sollpura to treat exocrine pancreatic insufficiency.
Develops Blisibimod for B-cell mediated autoimmune diseases.
Conducts Phase II clinical trials for Blisibimod to treat IgA nephropathy.
Establishes license agreements with pharmaceutical companies like Amgen and Eli Lilly.
Focuses on addressing unmet medical needs through innovative drug development.
Aims to improve patient outcomes and quality of life through targeted therapies.

Geschaeftsmodell

Develops and patents novel pharmaceutical products.
Conducts clinical trials to demonstrate safety and efficacy.
Seeks regulatory approval from agencies like the FDA.
Out-licenses or commercializes approved therapies.

Patients with exocrine pancreatic insufficiency (EPI).
Patients with B-cell mediated autoimmune diseases, including IgA nephropathy.
Healthcare providers who prescribe and administer Anthera's therapies.
Pharmaceutical companies that partner with Anthera through licensing agreements.

Patented drug formulations and delivery systems.
Clinical trial data demonstrating efficacy and safety.
Regulatory exclusivity for approved therapies.
Established partnerships with major pharmaceutical companies.

Katalysatoren

Upcoming: Results from Phase III clinical trial of Sollpura for exocrine pancreatic insufficiency.
Upcoming: Data readout from Phase II clinical trial of Blisibimod for B-cell mediated autoimmune diseases.
Ongoing: Potential for new licensing agreements with pharmaceutical companies.
Ongoing: Regulatory milestones and potential FDA approval for Sollpura.
Ongoing: Progress in expanding the company's pipeline through research and development.

Risiken

Potential: Failure of clinical trials for Sollpura or Blisibimod.
Potential: Regulatory setbacks and delays in drug approval process.
Ongoing: Competition from established pharmaceutical companies and emerging biotechs.
Ongoing: Limited financial resources and reliance on external funding.
Ongoing: OTC market listing indicating higher risk and volatility.

Staerken

Innovative pipeline of drug candidates targeting unmet medical needs.
Strategic partnerships with major pharmaceutical companies.
Potential for orphan drug designation for certain therapies.
Lean operational structure with a small team of employees.

Schwaechen

Limited financial resources and reliance on external funding.
High risk of clinical trial failures and regulatory setbacks.
Lack of established revenue streams and commercial infrastructure.
OTC market listing indicating higher risk and volatility.

Chancen

Expansion into new therapeutic areas and geographic markets.
Strategic acquisitions or licensing agreements to expand the pipeline.
Advancements in drug delivery technologies to improve efficacy.
Growing demand for therapies targeting rare diseases and autoimmune disorders.

Risiken

Competition from established pharmaceutical companies and emerging biotechs.
Changes in regulatory policies and reimbursement models.
Product liability claims and intellectual property disputes.
Economic downturns and market volatility affecting funding availability.

Wettbewerber & Vergleichsunternehmen

Comera Life Sciences Holdings, Inc. — Focuses on developing a new generation of bio therapeutics. — (CMRA)
Cotinga Pharmaceuticals Inc. — Develops therapeutics for cancer and other diseases. — (COTQF)
Guggenheim Active Allocation Fund — Financial services company. — (GBIM)
Nxt-ID, Inc. — Focuses on security and healthcare technology. — (NTII)
Ovita Therapeutics, Inc. — Unknown business focus. — (OVIT)

Key Metrics

Volume: 0
MoonshotScore: 41/100

Company Profile

CEO: Paul F. Truex
Headquarters: Houston, US
Employees: 21
Founded: 2010

AI Insight

AI analysis pending for ANTH

OTC Tier: OTC Other
Disclosure Status: Unknown

Fragen & Antworten

What does Anthera Pharmaceuticals, Inc. do?

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for patients with unmet medical needs. Their primary focus is on developing therapies for exocrine pancreatic insufficiency (EPI) and B-cell mediated autoimmune diseases. Their lead product candidates include Sollpura, a non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for EPI, and Blisibimod, a drug in Phase II clinical trials for autoimmune diseases. The company aims to improve patient outcomes by addressing conditions with limited treatment options.

What do analysts say about ANTH stock?

As of March 15, 2026, formal analyst ratings for Anthera Pharmaceuticals, Inc. (ANTH) are unavailable, likely due to its OTC listing and limited market capitalization. Given the company's focus on clinical-stage drug development, valuation is highly dependent on the success of Sollpura and Blisibimod clinical trials. Investors should closely monitor trial results and regulatory milestones, as these will be key drivers of future valuation. The company's financial position and cash runway are also critical factors to consider, given the high costs associated with drug development.

What are the main risks for ANTH?

Anthera Pharmaceuticals, Inc. faces significant risks inherent to the biotechnology industry and its OTC market listing. Clinical trial failures for Sollpura or Blisibimod would severely impact the company's value. Regulatory hurdles and delays in obtaining FDA approval pose additional risks. Competition from larger pharmaceutical companies with greater resources is a constant threat. The company's limited financial resources and reliance on external funding make it vulnerable to market conditions. The OTC listing increases volatility and reduces liquidity, posing challenges for investors.

Is ANTH a good investment right now?

Use the AI score and analyst targets on this page to evaluate Anthera Pharmaceuticals, Inc. (ANTH). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for ANTH?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates Anthera Pharmaceuticals, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find ANTH financial statements?

Anthera Pharmaceuticals, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.

What do analysts say about ANTH?

Analyst consensus targets and ratings for Anthera Pharmaceuticals, Inc. are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.

How volatile is ANTH stock?

Check the beta and historical price range on this page to assess Anthera Pharmaceuticals, Inc.'s volatility relative to the broader market.